1. Hyperkalemia as a limiting factor of neurohormonal blockade/modulation in everyday clinical practice
- Author
-
Henrique Vasconcelos, Joana Cabral, Emília Moreira, Manuel Campelo, Sandra Amorim, Brenda Moura, Alexandra Sousa, Roberto Pinto, Paulo Maia-Araújo, Cláudia Dias, and José Silva-Cardoso
- Subjects
Cardiology and Cardiovascular Medicine - Abstract
Neurohormonal blockade (NB)/modulation is the combination of two renin-angiotensin-aldosterone system inhibitors (RAASi) with a beta blocker. It is the core therapy for heart failure with reduced ejection fraction (HFrEF). While improving long term prognosis, it also induces hyperkalemia (serum KWe reviewed the medical records of HFrEF patients attending a HF clinic at a tertiary Portuguese hospital during 2018 (n=240). The number of patients not tolerating maximal neurohormonal blockade/modulation due to hyperkalemia was determined. The incidence and characteristics of hyperkalemia episodes were also assessed.Only six patients (3%) achieved maximal doses of neurohormonal blockade/modulation. Hyperkalemia was the limiting factor in 48 (20%) patients. A total of 185 hyperkalemia episodes occurred in 100 (42%) patients. Forty-five (24%) episodes were moderate or severe (serum KIn daily clinical practice, hyperkalemia is frequent and limits neurohormonal blockade/modulation by leading to the withholding or reducing of the intensity of RAAS inhibition. Considering the negative prognostic impact associated with sub-optimal neurohormonal blockade/modulation, addressing hyperkalemia is an important issue when treating HFrEF patients.
- Published
- 2022
- Full Text
- View/download PDF